NCT02201407View on ClinicalTrials.gov

An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 18, 2014

Primary Completion Date

April 10, 2017

Study Completion Date

April 10, 2017

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.

Trial Locations (6)

11000

Clinic for Gastroenterology and Hepatology, Belgrade

Clinical Center of Serbia; Institute For Infectious Diseases, Belgrade

11080

Clinical Center Zemun, Belgrade

18000

Clinic for Infectious Diseases CC Nis, Niš

21000

Clinical Center Vojvodine; Clinic for Infectious Diseases; Clinic for Hematology, Novi Sad

34000

Clinic for Infectious Diseases CC Kragujevac, Kragujevac

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02201407 - An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study | Biotech Hunter | Biotech Hunter